Allegro Ophthalmics Announces Positive Results of Vehicle-controlled Ex-U.S. Phase 2 Trial of ALG-1007 for the Treatment of Dry Eye Disease
Press release content from Business Wire. The AP news staff was not involved in its creation. Allegro Ophthalmics Announces Positive Results of Vehicle-controlled Ex-U.S. Phase 2 Trial of ALG-1007 for the Treatment of Dry Eye Disease July 24, 2021 GMT SAN JUAN CAPISTRANO, Calif.--(BUSINESS WIRE)--Jul 24, 2021-- Allegro Ophthalmics, LLC, a privately held biopharmaceutical company focused on the development of novel oxidative stress stabilizers for the treatment of ocular diseases, today announced that all primary and secondary endpoints of an ex-U.S. vehicle-controlled study of ALG-1007 topica...